Aktie A3C6ZG IO BIOTECH, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen IO Biotech, Inc.

Aktien

A3C6ZG

US4497781090

IOBT

Verzögert Nasdaq
Andere Börsenplätze
 19:25:53 31.05.2024 		% 5 Tage % 1. Jan.
1,2 USD -3,23 % Intraday Chart für IO Biotech, Inc. -5,51 % -36,17 %
15.05. IO BIOTECH, INC. : HC Wainwright bekräftigt seine Kaufempfehlung ZM
14.05. IO Biotech, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
IO BIOTECH, INC. : HC Wainwright réitère son opinion positive sur le titre
IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors
IO Biotech Announces Marjan Shamsaei as Senior Vice President
IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103
IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting
IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
IO Biotech Doses First Patient in Phase 2 Trial of Melanoma Treatment
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
IO Biotech Appoints Helen Collins, Md, to Its Board of Directors
IO Biotech Completes Enrollment in Pivotal Phase 3 Trial in Advanced Melanoma
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
IO Biotech, Inc. Announces Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology Congress
IO BIOTECH, INC. : Piper Sandler toujours positif
Transcript : IO Biotech, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 04:15 PM
IO Biotech Reports 'Encouraging' Data from Phase 2 Trial of IO102-IO103, Keytruda Combination to Treat Lung Cancer
IO BIOTECH, INC. : Opinion positive de Morgan Stanley
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3C6ZG Aktie
  4. Nachrichten IO Biotech, Inc.
  5. Andere Sprachen